

May 6, 2008

**APA DSM-V Work Group Member**

**Name, Degree:** Alan Budney, Ph.D.

**Role(s) in Work Group:** Member, Substance-Related Disorders Work Group

**Institutional Affiliation(s):** UAMS

**City, State:** Little Rock, AR

**Biographical Sketch:**

Dr. Alan J. Budney is a Professor in the Department of Psychiatry and Behavioral Sciences at the University of Arkansas for Medical Sciences. Over the last 15 years, he has conducted extensive research on the development and evaluation of behavioral treatments for cocaine and marijuana dependence. Most of his work has been supported by grants from the National Institute on Drug Abuse. His current research focuses on treatments for adult and adolescent marijuana abuse and the marijuana withdrawal syndrome. His recent outpatient human laboratory studies have established the timecourse, pharmaco-specificity, and clinical significance of marijuana withdrawal. His treatment development research has focused on demonstrating the efficacy of using incentives to enhance abstinence outcomes during and following treatment for marijuana abuse. Dr. Budney is a licensed psychologist and is a Fellow and Past-President of the Division of Psychopharmacology and Substance Abuse of the American Psychological Association, and has served on numerous ad hoc grant review committees at the NIH. He has also participated regularly with the Office of National Drug Control Policy on the Marijuana and Kids Media Campaign.

Dr. Budney received his undergraduate degree from Pennsylvania State University and his Masters and Doctoral degrees in Psychology from Rutgers, The State University of New Jersey. He completed a postdoctoral fellowship at the University of Vermont where he then joined the faculty. He eventually became a tenured Associate Professor in the Department of Psychiatry until he moved to the University of Arkansas for Medical Sciences in 2005.

**UNCOMPENSATED AFFILIATIONS WITH NON-PROFIT OR ADVOCACY ORGANIZATIONS THAT MAY HAVE A DIRECT OR INDIRECT INTEREST IN PSYCHIATRIC DIAGNOSIS, TREATMENT, OR THE DSM-V : CALENDAR YEARS 2005, 2006, 2007, AND FOR 2008, ACTIVITIES TO DATE AND COMMITMENTS FOR REMAINDER OF YEAR.**

<b>Non-Profit and Advocacy Organizations</b>	<b>Year(s)</b>	<b>Role</b>
American Psychological Association - Division of Substance Abuse and Psychopharmacology,	2005, 2006, 2007	President Elect, President, Past-President

The two tables below represent Dr. Budney's disclosure of significant interests and affiliations for: (1) The full calendar years of 2005, 2006, and 2007; and (2) for 2008, interests and affiliations to date and commitments for remainder of year.

Dr. Budney has agreed that, from the time of approval through the publication of DSM-V, projected in 2012, (his/her) aggregate annual income derived from industry sources (excluding unrestricted research grants) will not exceed \$10,000 in any calendar year.

<p><b>KEY NUMBER:</b></p> <p>1. Consultation Fees (include scientific advisory boards)</p> <p>2. Full- or Part-time Employee</p> <p>3. Industry-related Grant-Research Support received or pending</p> <p>4. Honoraria (includes Speakers' Bureau)</p> <p>5. Stock or other financial options</p>	<p>6. Expert testimony</p> <p>7. Royalties (including right to share of revenue or profit from pharmaceutical, device or other development or product)</p> <p>8. Patents received or pending</p> <p>9. Officer, director/trustee, executive (specify)</p> <p>10. Other (specify)</p>
---	--

**DISCLOSURE OF SIGNIFICANT INTERESTS FOR 2005, 2006, AND 2007**

<b>Commercial or Other Organization</b>	<b>Year(s)</b>	<b>Key #(s)</b>
Sanofi	2005	3

**DISCLOSURE OF SIGNIFICANT INTERESTS TO DATE FOR 2008 AND COMMITMENTS FOR REMAINDER OF YEAR**

<b>Commercial or Other Organization</b>	<b>Year(s)</b>	<b>Key #(s)</b>
National Cannabis Prevention and Information Centre (Australia)	2008	1, 4